# Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions

> **NCT00301522** · PHASE2,PHASE3 · COMPLETED · sponsor: **Boston Scientific Corporation** · enrollment: 1108 (actual)

## Conditions studied

- Coronary Stenosis

## Interventions

- **DEVICE:** TAXUS Paclitaxel-Eluting Coronary Stent, Slow-Formulation
- **DEVICE:** Express2

## Key facts

- **NCT ID:** NCT00301522
- **Lead sponsor:** Boston Scientific Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2004-12
- **Final completion:** 2009-04
- **Target enrollment:** 1108 (ACTUAL)
- **Last updated:** 2010-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00301522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00301522, "Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00301522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*